You are here:
Publication details
Clinical-Grade Human Embryonic Stem Cells and Their Use in Stem Cell Therapy
| Authors | |
|---|---|
| Year of publication | 2026 |
| Type | Appeared in Conference without Proceedings |
| MU Faculty or unit | |
| Citation | |
| Attached files | |
| Description | Human embryonic stem cells (hESCs) possess an exceptional self-renewal capacity and the ability to differentiate into all somatic cell types, making them a fundamental resource for cell-based therapies, disease modelling, and drug development. The generation of clinicalgrade cell lines, however, is an exceptionally demanding process that requires strict cleanroom operations, extensive quality testing, rigorous documentation, validated procedures, and highly trained personnel capable of maintaining full compliance with Good Manufacturing Practice (GMP) standards. Each step must be meticulously controlled to ensure safety, traceability, and reproducibility—factors that significantly increase the complexity, cost, and time required for successful derivation. Despite these challenges, the therapeutic potential of hESCs remains remarkable. Their ability to generate specialised cell types offers opportunities to treat a wide spectrum of currently incurable conditions, including neurodegenerative diseases, metabolic disorders, cardiac damage, and degenerative eye diseases. Continued investment in hESC research is therefore essential, as it opens the door to transformative therapies capable of restoring lost tissue function and improving patients’ quality of life. Within our Cell and Tissue Facility at St. Anne’s University Hospital, we have successfully derived three clinical-grade hESC lines, representing a major milestone in our translational research programme. Building on this foundation, we are advancing their differentiation into retinal pigment epithelium (RPE) cells for the treatment of age-related macular degeneration. We have already developed a fully GMP-compliant differentiation protocol and completed all required quality assays, positioning us to advance hESC-derived RPE therapy towards clinical application. With continued progress, collaboration, and innovation, these efforts pave the way towards safe and effective regenerative treatments that may soon become a reality for patients who currently have no therapeutic alternatives. This research was supported by the Ministry of Health of the Czech Republic, Grant No. NU2208-00629. Supported by the European Regional Development Fund - project CZECRIN_PHARMTECH, No. CZ.02.01.01/00/23_015/0008194. |
| Related projects: |